GSK Ebola vaccine first to undergo EMA rapid advice procedure
This article was originally published in SRA
Executive Summary
The European Medicines Agency said GlaxoSmithKline's experimental Ebola vaccine is the first product to undergo a new regulatory process aimed at allowing companies developing products against the deadly virus to receive "rapid scientific advice" with the intent of accelerating the assessment processes1.